Effects of neoadjuvant chemotherapy on minimum alveolar concentration values of sevoflurane and desflurane in patients with hepatocellular carcinoma complicated with jaundice

Zhang,Lin; Zuo,Mingyan; Ma,Xinxin; Dong,Youhong

doi:10.3892/ol.2018.8621

Effects of neoadjuvant chemotherapy on minimum alveolar concentration values of sevoflurane and desflurane in patients with hepatocellular carcinoma complicated with jaundice

Authors:
- Lin Zhang
- Mingyan Zuo
- Xinxin Ma
- Youhong Dong
View Affiliations

Affiliations: Department of Pharmacy, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China, Departments of Pulmonary Disease, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China, Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
Published online on: May 2, 2018 https://doi.org/10.3892/ol.2018.8621
Pages: 388-394

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effects of neoadjuvant chemotherapy on the minimum alveolar concentration (MAC) values of sevoflurane and desflurane in patients with hepatocellular carcinoma (HCC) complicated with jaundice were investigated. Eighty patients with HCC complicated with jaundice were selected. Forty patients underwent the neoadjuvant chemotherapy and were grouped into the desflurane group (Group D) and the sevoflurane group (Group S). Patients in all chemotherapy groups received 2 cycles of chemotherapy prior to surgery and underwent surgical treatment 3 weeks after chemotherapy. The remaining 40 patients in the control group were divided into the desflurane group (Group C1) and the sevoflurane group (Group C2). Changes in MAP, HR and BIS at different time points before and after anesthesia induction and skin incision were compared among the groups. Results showed that there were no significant differences in MAP, HR and BIS before anesthesia induction (T0) (P>0.05); at each time point from T1 to T6, MAP, HR and BIS of Group D were significantly lower than those of Group C1 (P>0.05). Furthermore, MAP, HR and BIS of Group S were significantly lower than those of Group C2 (P>0.05). The MACMean of sevoflurane and desflurane were compared among all patient groups using the mean method. MACMean values of Group D were significantly lower than those of Group C1 (P<0.05). Notably, MACDixon values of sevoflurane and desflurane were compared among all patient groups using the Dixon method and the differences were statistically significant (P<0.05). Logistic regression analyses were conducted, respectively, which revealed that the MAC of sevoflurane and desflurane were associated with whether patients received the neoadjuvant chemotherapy. MACLog of sevoflurane and desflurane were decreased in patients receiving the neoadjuvant chemotherapy. The results suggested that neoadjuvant chemotherapy can reduce MAC values of sevoflurane and desflurane in HCC patients complicated with jaundice and may improve these patients' sensitivity to sevoflurane and desflurane.

View Figures

View References

1	Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, et al: Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). Eur J Surg Oncol. 43:1550–1558. 2017. View Article : Google Scholar : PubMed/NCBI
2	Kümmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, Gerber B, Hanusch C, Hilfrich J, et al: Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 84:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
3	Feng X, Chen A, Zhang Y, Wang J, Shao L and Wei L: Central nervous system toxicity of metallic nanoparticles. Int J Nanomedicine. 10:4321–4340. 2015.PubMed/NCBI
4	Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA and Tannock IF: The effects of chemotherapy on cognitive function in a mouse model: A prospective study. Clin Cancer Res. 18:3112–3121. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sipocz I, Pinter T, Skaliczky Z and Kullmann T: Effective systemic palliative chemotherapy for intracranial metastases of breast cancer. Orv Hetil. 157:1809–1813. 2016.(In Hungarian). PubMed/NCBI
6	Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion VL, Schneider BP and Saykin AJ: Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 34:677–683. 2016. View Article : Google Scholar : PubMed/NCBI
7	He ZJ, Hu YH and Fan ZY: Median effective effect-site concentration of intravenous anesthetics for loss of consciousness in neoadjuvant chemotherapy patients. Chin Med J (Engl). 124:504–508. 2011.PubMed/NCBI
8	Trenerry C, Peters MDJ, Corsini N, Damarell RA, Wilson C and Flight I: Patient-reported outcomes following neoadjuvant chemotherapy or chemoradiotherapy treatment for esophageal cancer: A scoping review protocol. JBI Database System Rev Implement Rep. 15:1499–1507. 2017. View Article : Google Scholar : PubMed/NCBI
9	Weng Y, Yang L, Corringer PJ and Sonner JM: Anesthetic sensitivity of the Gloeobacter violaceus proton-gated ion channel. Anesth Analg. 110:59–63. 2010. View Article : Google Scholar : PubMed/NCBI
10	Liang Q, Anderson WD, Jones ST, Souza CS, Hosoume JM, Treptow W and Covarrubias M: Positive allosteric modulation of Kv channels by sevoflurane: Insights into the structural basis of inhaled anesthetic action. PLoS One. 10:e01433632015. View Article : Google Scholar : PubMed/NCBI
11	Klock PA Jr, Czeslick EG, Klafta JM, Ovassapian A and Moss J: The effect of sevoflurane and desflurane on upper airway reactivity. Anesthesiology. 94:963–967. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kotwani MB and Malde AD: Comparison of maintenance, emergence and recovery characteristics of sevoflurane and desflurane in pediatric ambulatory surgery. J Anaesthesiol Clin Pharmacol. 33:503–508. 2017.PubMed/NCBI
13	Costi D, Cyna AM, Ahmed S, Stephens K, Strickland P, Ellwood J, Larsson JN, Chooi C, Burgoyne LL and Middleton P: Effects of sevoflurane versus other general anaesthesia on emergence agitation in children. Cochrane Database Syst Rev. 12:CD0070842014.
14	Chen VE, Gillespie EF, Zakeri K, Murphy JD, Yashar CM, Lu S and Einck JP: Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer. Adv Radiat Oncol. 2:105–109. 2017. View Article : Google Scholar : PubMed/NCBI
15	Mirkin KA, Luke FE, Gangi A, Pimiento JM, Jeong D, Hollenbeak CS and Wong J: Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: A multi-institutional analysis. J Gastrointest Oncol. 8:589–595. 2017. View Article : Google Scholar : PubMed/NCBI
16	Hentic O, Safi D, Jerome C, Magaly Z, Vinciane R, Sebastien G, Frederique M, Anne C, Philippe L, Philippe R, et al: Neoadjuvant gemcitabine-oxaliplatin (GemOx) combination followed by chemoradiotherapy (CRT) in borderline pancreatic adenocarcinoma (BPC): A promising management. Pancreatology. 15 Suppl:S1122015. View Article : Google Scholar
17	Seigers R, Loos M, Van Tellingen O, Boogerd W, Smit AB and Schagen SB: Cognitive impact of cytotoxic agents in mice. Psychopharmacology (Berl). 232:17–37. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zhou C, Liang P, Liu J, Ke B, Wang X, Li F, Li T, Bayliss DA and Chen X: HCN1 channels contribute to the effects of amnesia and hypnosis but not immobility of volatile anesthetics. Anesth Analg. 121:661–666. 2015. View Article : Google Scholar : PubMed/NCBI
19	Sun X, Liu J, Wang Y, Bai X, Chen Y, Qian J, Zhu H, Liu F, Qiu X, Sun S, et al: Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget. 8:49156–49164. 2017.PubMed/NCBI
20	Lutterbeck CA, Kern DI, Machado ÊL and Kümmerer K: Evaluation of the toxic effects of four anti-cancer drugs in plant bioassays and its potency for screening in the context of waste water reuse for irrigation. Chemosphere. 135:403–410. 2015. View Article : Google Scholar : PubMed/NCBI
21	Liu X, Dingley J, Elstad M, Scull-Brown E, Steen PA and Thoresen M: Minimum alveolar concentration (MAC) for sevoflurane and xenon at normothermia and hypothermia in newborn pigs. Acta Anaesthesiol Scand. 57:646–653. 2013. View Article : Google Scholar : PubMed/NCBI
22	Mishra RK, Mahajan C, Prabhakar H, Kapoor I and Bithal PK: Effect of nitrous oxide on bispectral index values at equi-minimum alveolar concentrations of sevoflurane and desflurane. Indian J Anaesth. 61:482–485. 2017. View Article : Google Scholar : PubMed/NCBI
23	Du W, Li C, Wang H, Zhao A, Shen J, Yong F and Jia H: Effect of neoadjuvant chemotherapy on sevoflurane MAC-BAR value of patients undergoing radical stomach carcinoma surgery. Int J Clin Exp Med. 8:5649–5657. 2015.PubMed/NCBI
24	Voulgaris DA, Egger CM, Seddighi MR, Rohrbach BW, Love LC and Doherty TJ: The effect of nitrous oxide on the minimum alveolar concentration (MAC) and MAC derivatives of isoflurane in dogs. Can J Vet Res. 77:131–135. 2013.PubMed/NCBI
25	Suarez MA, Seddighi R, Egger CM, Rohrbach BW, Cox SK, KuKanich BK and Doherty TJ: Effect of fentanyl and lidocaine on the end-tidal sevoflurane concentration preventing motor movement in dogs. Am J Vet Res. 78:12–16. 2017. View Article : Google Scholar : PubMed/NCBI